This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Transparency & HCP Engagement 2025
Delivered as a Hybrid Event August 12-14, 2025
The Ritz-Carlton, Tysons CornerMcLean, VA

Amanda Masselam Strachan
Partner at WilmerHale
Speaker

Profile

Amanda Masselam Strachan is a seasoned trial lawyer who advises clients in corporate investigations and litigation with an emphasis on white-collar criminal defense and health care fraud enforcement. She leverages her eighteen years as a federal prosecutor, including her roles as Chief of the Criminal Division and Chief of the Health Care Fraud Unit for the US Attorney’s Office for the District of Massachusetts, to help clients navigate complex legal questions arising from the inquiries of federal and state prosecutorial authorities, regulators, and private litigants. Ms. Masselam Strachan has extensive experience conducting corporate investigations and trying complex cases. She is a member of the firm's industry-leading White-Collar Defense and Investigations practice.

Ms. Masselam Strachan was a national leader in DOJ's efforts to combat fraud and abuse in the health care industry. She prosecuted and tried some of the most high-profile prosecutions in the district, including the New England Compounding Center (NECC) cases, in which she convicted following multiple jury trials executives, owners, and other individuals associated with the compounding pharmacy, which was responsible for producing contaminated steroids that caused the nationwide fungal meningitis outbreak. She handled several other landmark health care fraud cases, including the $650 million settlement with a strategy and management consulting firm for its work advising opioid manufacturers; the criminal prosecution of Insys Therapeutics, Inc. for fraud and paying kickbacks through its speaker programs; and a $3 billion global plea and settlement with a pharmaceutical and biotechnology company relating to allegations of misbranding under the FDCA.

Agenda Sessions

  • Enforcement Update – Examining Today’s Regulatory Landscape and Emerging Trends

    11:15am